CCCC C4 Therapeutics, Inc.
Healthcare$3.56+1.14%ClosedMarket Cap: $294.9M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.92
P/S
8.46
EV/EBITDA
-2.70
DCF Value
$-2.93
FCF Yield
-32.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.8%
Operating Margin
-326.6%
Net Margin
-297.8%
ROE
-50.7%
ROA
-31.6%
ROIC
-36.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $6.2M | 70.7% | $-27.8M | $-25.1M | $— | — |
| Q4 null | $11.0M | 100.0% | $-23.1M | $-20.5M | $— | — |
| FY null | $35.9M | 77.8% | $-104.5M | $-105.0M | $— | — |
| Q3 null | $11.2M | 100.0% | $-34.4M | $-32.2M | $— | — |
| Q2 null | $6.5M | 100.0% | $-28.5M | $-26.0M | $— | — |
| Q1 null | $7.2M | 100.0% | $-29.2M | $-26.3M | $— | — |
| Q4 null | $5.2M | 65.9% | $-37.7M | $-34.6M | $— | — |
| FY null | $35.6M | 100.0% | $-119.6M | $-105.3M | $— | — |
| Q3 null | $15.4M | 86.6% | $-28.2M | $-24.7M | $— | — |
| Q2 null | $12.0M | 83.0% | $-21.4M | $-17.7M | $— | — |
| Q1 null | $3.0M | 100.0% | $-32.2M | $-28.4M | $— | — |
| Q4 2023 | $3.3M | 48.1% | $-37.4M | $-34.8M | $-0.68 | — |